drugset / Trial / NCT04572477

The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome

NCT04572477

Phase 2 Unknown 200 enrolled Chang Gung Memorial Hospital
Non-randomizedParallel-groupSingle-blindDiagnostic

Summary

Amyloid plaques and tau protein are the landmarks of neurodegeneration in Alzheimer's disease (AD). On the other hand, it is reported that cerebral ischemia may induce amyloid plaques and tau protein accumulation. However, it was difficult to in vivo disentangle the complex and dynamic interactions between AD pathophysiology and cerebral vascular injury in the development of post-stroke cognitive impairment in the past. With the advent of novel radiotracers specific to cerebral amyloid plaques and tau protein, we aim to conduct a prospective multimodal neuroimaging cohort study to investigate the contribution of vascular injury, amyloid plaques and tau protein to stroke recovery and post-stroke cognitive impairment.

Timeline

Start
2017-06-01
Primary completion
2023-11-30
Completion
2024-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]THK-5351 Diagnostic / imaging agent
Subject florbetapir F 18 Diagnostic / imaging agent

Indications